TY - JOUR
T1 - Pemetrexed in the treatment of selected solid tumors
AU - Adjei, Alex A.
N1 - Funding Information:
Dr Adjei has received research grant support from Eli Lilly and Co.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2002
Y1 - 2002
N2 - The novel agent pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Significant activity has been seen in completed phase II trials of pemetrexed in non-small cell lung cancer and breast cancer. Pemetrexed is also active in combination with other agents such as gemcitabine, cisplatin, and carboplatin. In addition, this agent shows promising activity in bladder, head and neck, esophageal, renal, and cervical carcinomas. Preliminary results of studies in these tumor types are reviewed.
AB - The novel agent pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Significant activity has been seen in completed phase II trials of pemetrexed in non-small cell lung cancer and breast cancer. Pemetrexed is also active in combination with other agents such as gemcitabine, cisplatin, and carboplatin. In addition, this agent shows promising activity in bladder, head and neck, esophageal, renal, and cervical carcinomas. Preliminary results of studies in these tumor types are reviewed.
UR - http://www.scopus.com/inward/record.url?scp=0036264671&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036264671&partnerID=8YFLogxK
U2 - 10.1016/s0093-7754(02)70216-9
DO - 10.1016/s0093-7754(02)70216-9
M3 - Review article
C2 - 12023793
AN - SCOPUS:0036264671
SN - 0093-7754
VL - 29
SP - 50
EP - 53
JO - Seminars in oncology
JF - Seminars in oncology
IS - 2 SUPPL. 5
ER -